U.S. Tobacco Stock News

Calumet stock dropped 5.7% to close at US$39.48 after its latest earnings, even though the quarter featured one clear headline. The company produced US$175m of adjusted earnings before interest, tax, depreciation and amortization, and generated more than US$90m of cash from operations, while continuing to pay down debt. In the short term, traders are reacting to a red price screen. Over a multi year horizon, the real story is the balance sheet repair. Management is retiring higher cost...

Array Digital Infrastructure came into this earnings release with a bruised share price and a value label. The stock has fallen about 33% over the past three months, yet still trades on a trailing P/E of 4.6x compared with much richer wireless tower peers. Then Q2 landed with a jolt. Basic earnings per share jumped to US$3.86 and net income from ongoing operations reached US$333.77 million. The market barely flinched, with the stock slipping 1.1% to US$35.24 after the report. That muted move...

United Community Banks (NYSE:UCB) appointed Carl S. Carande to its Board of Directors and Risk Committee. Carande is a former KPMG International Head of Global Advisory with roughly four decades of financial services and consulting experience. The appointment adds expertise in global risk, technology, and organizational strategy to United Community Banks' governance structure. For more context on where United Community Banks fits within the sector, consider exploring other bank and...

Star Bulk Carriers has delivered a 151.7% total return over the past five years, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and market multiples still point to the stock trading at a discount of around 40.1% to fair value. That mix of strong long term performance and ongoing valuation gap is drawing fresh attention after the latest earnings update and fleet expansion plans. Over five years the stock is up 151.7%, which means long term holders have already seen...

Fluor stock just put in a 16.9% one day jump, and that kind of move demands a sanity check. The headline is not a one off accounting quirk. Investors are reacting to a construction and engineering giant that delivered Q2 revenue of US$4.3b and adjusted earnings per share of US$0.91, while locking in US$6.1b of new awards and pushing backlog toward US$27b. The real story is whether this surge reflects a clean reset of sentiment on Fluor’s order book and earnings power, or if buyers are...

BlackLine's share price has fallen sharply over the past five years, yet the valuation checks now suggest the stock is closer to fairly priced than a clear bargain or an obvious excess. BlackLine has declined 73.6% over the past five years, which puts a lot of past optimism into question and makes the current price more about what happens next than what has happened so far. The recent launch of Verity Prepare AI can support the case for better long term economics if adoption is strong, while...

Why Gulfport Energy’s latest quarter is drawing attention Gulfport Energy (GPOR) has moved into focus after second quarter results showed lower quarterly revenue, net income, and production, alongside fresh full year production guidance and the upcoming resignation of its Chief Financial Officer. For you as an investor, this cluster of updates raises several questions. The mix of softer quarterly metrics, leadership change at the finance helm, and new production targets can influence how you...

Trip.com Group stock has delivered an 86.1% gain over the past 5 years, yet the broader valuation checks still suggest the shares lean cheap. Recent share price weakness in 2026 leaves investors weighing that longer term return against a high value score and mixed shorter term performance. Over 5 years, Trip.com Group is up 86.1%, which points to meaningful value creation for longer term holders despite recent setbacks. The 2025 Sustainability Report and the new US$100 million Tourism...

Douglas Elliman slipped 0.6% to US$1.78 after its second quarter report, a muted move for a stock tied to luxury housing sentiment. The headline is not the price; it is the sharp improvement in the income statement. Revenue was US$283.4m and the quarterly loss narrowed to US$2.7m. For a brokerage that only recently turned profitable on a trailing basis, that combination turns today’s dip into a sentiment check rather than a clear verdict. The rest of the report shows how fragile or durable...

In the second quarter of 2026, Upbound Group, Inc. reported sales of US$903.7 million, revenue of US$1.16 billion, and net income of US$21.58 million, with basic earnings per share from continuing operations of US$0.37, all modestly higher than a year earlier. The company also narrowed its full-year 2026 consolidated revenue outlook to US$4.70–US$4.85 billion and issued third-quarter revenue guidance of US$1.05–US$1.15 billion, giving investors a clearer view of expected scale and earnings...

A surprise loss of 23,000 US jobs in July and softer wage growth has put resilience back in the spotlight. Healthcare giants in areas such as pharmaceuticals and medical equipment are often watched closely when the broader economy looks less certain, because demand for many treatments can remain steady. This article reveals 3 large healthcare stocks from our screener that appear well placed against this backdrop. The three stocks highlighted below are just a sample from this theme, with the...

Regulatory milestone puts focus on GRAIL stock GRAIL (GRAL) is in the spotlight after the FDA scheduled a September 23, 2026 advisory committee meeting to review the Premarket Approval application for its Galleri multi cancer early detection blood test. See our latest analysis for GRAIL. The FDA panel date has come alongside GRAIL’s recent Q2 update and a sharp 1 day share price return of 9.59%, even though the year to date share price return is down 21.82%. Over the past year, the total...

Biglari Holdings stock barely flinched after earnings, easing just 0.3%, yet the headline result was anything but quiet. A swing to basic earnings per share of US$158.17 for the quarter, alongside net income of US$39.93 million, marks a sharp break from the recent run of losses. The market still treats Biglari as an unprofitable story with stretched valuation, which sets up a sentiment clash between the trailing weakness and a powerful single quarter of profitability. Is Biglari Holdings now...

In late July 2026, Align Technology reported second-quarter 2026 results showing sales rising to US$1,056.19 million year-on-year, issued softer sequential revenue guidance for the third quarter, and outlined the impact of one-time restructuring, depreciation, and legal charges on its GAAP operating margin outlook. At the same time, after discussions with Elliott Investment Management, Align committed to appoint three new independent directors, launched a comprehensive strategic and...

With the Iran war disrupting the Strait of Hormuz, inflation staying stubbornly high and rate hikes still on the table, many investors are questioning how much risk is really baked into today’s lofty valuations. Periods like this can punish fragile business models but also reveal sturdier ones. This article focuses on 3 large cap value stocks that screens suggest are more exposed to these shocks, and explains what that could mean for your portfolio decisions. The three stocks below are only a...

FIGS stock has delivered a very strong 129.3% return over the past year, yet its valuation checks still suggest the shares are not an obvious bargain. Recent optimism around growth and profitability now sits alongside a low overall value score and an assessment that the stock screens as overvalued on market multiples. The 129.3% one year return signals that expectations around FIGS have shifted quickly and that recent buyers are paying a much higher price than they were a year ago. Stronger...

In the second quarter of 2026, Biogen Inc. reported revenue of US$2,736.0 million, up from US$2,645.5 million a year earlier, while net income fell to US$97.5 million and diluted earnings per share from continuing operations declined to US$0.66 from US$4.33. Despite higher sales and revenue, Biogen’s earnings compressed significantly, even as its newer therapies outpaced its legacy multiple sclerosis portfolio and the Apellis acquisition expanded its growth product lineup. We’ll now examine...

TOMS Capital’s no confidence campaign against Voya Financial (VOYA) has moved into a new phase, with a definitive proxy filing and an open letter challenging the board’s decisions, recent execution, and approach to potential third party interest. See our latest analysis for Voya Financial. At a share price of US$101.40, Voya Financial has delivered a 26.54% 90 day share price return and a 46.36% 1 year total shareholder return. This suggests recent momentum has been strong despite the fresh...

D.R. Horton stock has delivered a 62.8% gain over the past five years, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and earnings multiples currently point to the shares trading below what those frameworks suggest as fair. Over the last five years, D.R. Horton has returned 62.8%, which means long term holders have already seen solid value creation even before considering today’s valuation signals. Market expectations for future housing demand and construction activity can...

ANI Pharmaceuticals just took a 5.3% hit in a single session, yet the earnings story looks more like growing pains than a broken thesis. You have a stock that came into the print soft over the past month, then sold off again right after reporting adjusted earnings per share of US$2.21 on revenue of US$266.0m. The real swing factor is profit quality. Investors appear to be wrestling with how much of the recent profitability and trailing US$259.6m of adjusted EBITDA reflects repeatable rare...

Embecta entered this quarter wearing the label of a deeply discounted diabetes device stock, with a single digit P/E and significant balance sheet questions. The market lifted the share price 26% to US$4.42 in the first session after earnings. The move reflects one headline takeaway: the business reported a sharp rebound in both revenue and profit, with Q3 sales of US$271.7m and net income of US$21.1m after a loss in Q2. For a company under pressure over debt and cash generation, that...

How PayPal's Latest Earnings Set the Stage for Investors PayPal Holdings (PYPL) just reported second quarter 2026 results, with sales of US$8.68b and net income of US$1.10b, giving investors a mixed update on growth and profitability. Sales for the first half of 2026 reached US$17.04b, while net income for the same period came in at US$2.22b. Earnings per share from continuing operations were lower than a year ago on both a basic and diluted basis. At the same time, PayPal Holdings (PYPL)...

In late July 2026, Laureate Education, Inc. reported second-quarter sales of US$615.86 million and net income of US$137.1 million, alongside higher first-half earnings and an updated full-year 2026 revenue outlook of US$1.92 billion to US$1.93 billion, implying 13% as-reported growth. At the same time, Laureate expanded its share repurchase effort, having already bought back 13,863,000 shares for US$399.61 million and adding a further US$250 million authorization, highlighting management’s...

Under Armour stock fell about 4.5% to US$6.11 in the first trading session after its Q1 2027 report, adding fresh pressure to an already weak one month stretch. At first glance the reaction looks harsh for a company that just posted a small profit and stronger than expected adjusted operating income. The real headline is not the quarter. It is the decision to cut full year revenue guidance to a mid single digit decline while still holding the US$140 million to US$160 million adjusted...